Skip to main content

Ocriplasmin Recommended for Vitreomacular Adhesions


July 27, 2012 — An advisory committee to the US Food and Drug Administration (FDA) voted July 26 to recommend ocriplasmin (Jetrea, ThromboGenics, Inc) 125 μg intravitreal injection for the treatment of symptomatic vitreomacular adhesions (sVMAs), including macular hole.
The committee voted unanimously to recommend approval of ocriplasmin for the treatment of VMAs, and 7 to 3 in favor of recommending approval for treatment of macular holes. "I thought the anatomic data was very favorable," Stephen S. Feman, MD, MPH, a professor at Saint Louis University School of Medicine in Missouri and voting committee member, said during the advisory meeting.
Symptomatic VMAs result from incomplete separation of the vitreous from the macula and can be progressive and result in blindness. At this time, the only treatment option is vitrectomy, a major surgical procedure that is usually postponed until late in the disorder because of the potential risks and difficult recovery period. Ocriplasmin is the first pharmacologic treatment for symptomatic VMAs and could improve outcomes by making treatment available earlier.
Ocriplasmin is a recombinant truncated form of the human serine protease plasmin with retained enzymatic activity that acts on collagen, fibronectin, and laminin to liquefy the vitreous, resulting in its detachment from the macula.
The committee discussed data from 2 randomized, phase 3, placebo-controlled studies, TG-MV-006 and TG-MV-007. Each study had 326 participants, and a total of 652 eyes were injected.
The studies enrolled patients with sVMA, which was described as vitreomacular traction with or without a full-thickness macular hole.
Patients were seen for 7 visits during a 6-month period: at baseline and on injection day (day 0), postinjection day 7, postinjection day 14, postinjection day 28, postinjection month 3, and postinjection month 6.
Efficacy
The primary efficacy endpoint was the proportion of patients whose focal VMA resolved without surgery at day 28 postinjection, as determined by masked central reading center optical coherence tomography evaluation.
The secondary efficacy endpoint was the proportion of patients who had total posterior vitreous detachment at day 28, as determined by masked investigator assessment of B-scan ultrasound.
Primary endpoints were achieved in each study, and statistically significantly higher VMA resolution rates were seen at day 28 in patients who received a single injection of 125 μg ocriplasmin compared with placebo.
In study TG-MV-006, 13.1% (n = 107) of patients who received placebo and 27.9% (n = 219) of patients who received ocriplasmin met primary efficacy endpoints.
In study TG-MV-007, 6.2% (n = 81) of patients who received placebo and 25.3% (n = 245) of patients who received ocriplasmin met primary efficacy endpoints.
Safety
Data from a total of 7 completed studies, including TG-MV-006 and TG-MV-007, also were analyzed for safetyas well. Of note, 9 of 976 ocriplasmin-treated patients experienced temporary, postinjection serious and/or severe adverse events that involved acute vision decrease within 24 hours of injection. Vision returned to at least pretreatment levels (median time, 2 weeks) in all but 1 patient, whose vision decrease was considered to be related to concurrent retinal disease. The reasons for this are unclear.
A total of 8 patients from the 7 studies died; 6 were in the treatment group and 2 were in the placebo group. None of the deaths were related to treatment.
"The majority of patients who receive this drug will not get benefit from the drug, and I think that that needs to be very clearly stated. If the drug is approved, it must be very clearly stated in labeling.... Even though there is efficacy benefit over risk...the majority of patients will not see a benefit from this drug," said Lynn Gordon, MD, PhD, a professor of ophthalmology at Jules Stein Eye Institute and associate dean of diversity affairs at David Geffen School of Medicine at the University of California, Los Angeles, and voting committee member, said during the advisory meeting.
"I agree with [Dr. Gordon's] concerns, but I suspect that the sponsor will look at, and the ophthalmology community will identify, which patients have a higher potential for benefit with this treatment," said Susan MacDonald, MD, director of comprehensive ophthalmology and assistant professor at Tufts University School of Medicine, Boston, Massachusetts, also a voting committee member, said during the advisory meeting.
"I believe that if you can reduce the number of people that need vitrectomy by 25% by using this medication, you're really making a benefit to mankind," said Dr. Feman.
No relevant financial relationships were disclosed by the voting committee members. The industry representative is employed by Forest Laboratories.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more